News
Regeneron price target lowered to $1,081 from $1,150 at Morgan Stanley TipRanks Apr. 9, 2025, 06:17 AM ...
Meanwhile, JPMorgan categorized Regeneron (REGN) and Merck (MRK) as "out of favor" names, suggesting investors are focusing on stronger core assets and upcoming launches rather than uncertainty.
JPMorgan (NYSE: JPM) told investors in a note Monday that Eli Lilly & Co. (NYSE: LLY) shares are its “top pick” among U.S.
Hosted on MSN2mon
Regeneron slumps as Wells Fargo cuts on COPD trial data - MSN
Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...
JP Morgan maintains its Neutral rating on Regeneron Pharmaceuticals, which is currently trading down $6.84 form yesterday's $127.85 closing price.
In a report released yesterday, Matthew Harrison from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $883.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback